This testing has shown the active ingredient in Sublimiss to yield the same anti-depressant properties as the Valium class drugs with no reported side effects. In Central Nervous System receptor binding assays the compound found in Sublimiss is bound to several important targets including the serotonin transporter. It does not bind to the benzodiazepine receptors that would cause sedation, yet has the relaxing qualities of the benzodiazepine class of drugs in validated anxiolytic animal models.
Anxiety is being show to play a significant role in a wide variety of conditions and disease states.
Recent work from the National Institute of Health and other major research centers has demonstrated that anxiety is a significant contributor to excess body fat, immune dysfunction, cardiovascular disease and other age-related disorders. Pharmaceutical companies with anxiolytic drugs have launched major consumer advertising campaigns that are fueling the awareness of the problems while building a market for products that can be used to treat anxiety and related conditions. Sublimiss contains the first natural ingredient to be specifically targeted to anxiety and well capitalize on the awareness being generated the the pharmaceutical industry. Fifty subjects were tested with the main component in Sublimiss for two weeks. The dosage was applied three times daily with the majority of the subjects taking less than the recommended dose.